拉米夫定治疗乙型肝炎肝衰竭对患者HBVDNA的干预作用

摘要

目的 探讨拉米夫定治疗乙型肝炎肝衰竭对患者HBV-DNA的干预作用. 方法 研究对象整群选取于该院2012年12月—2014年12月收治的74例慢加急性乙型肝炎肝衰竭患者,按随机数字表法分为对照组与观察组,各37例.对照组患者接受常规基础治疗;观察组患者同时给予拉米夫定治疗. 统计两组患者治疗前后血清总胆红素(TBiL)水平、凝血酶原活动度(PTA)及乙肝病毒基因(HBVDNA)载量. 结果 治疗后,较对照组,观察组TBiL(93.52±56.31)μmol/L和HBV-DNA(4.15±1.54)lg IU/mL低,PAT(63.54±3.69)高,两组比较差异均有统计学意义(P<0.05).结论 拉米夫定治疗乙型肝炎肝衰竭患者疗效确切,能有效降低血清HBV-DNA水平,抑制病毒复制.%Objective To observe the intervention effect of lamivudine in treatment of hepatitis B liver failure on HBVDNA in patients. Methods 74 cases of patients with acute-on-chronic hepatitis B liver failure treated in our hospital from De-cember 2012 to December 2014 were selected as the research object and randomly divided into two groups with 37 cases in each, the control group were given conventional basis treatment, the observation group were given lamivudine treatment at the same time, the serum total bilirubin level (TBiL), prothrombin Activity (PTA) and hepatitis B virus gene capacity of the two groups before and after treatment were given statistics. Results After treatment, the TBiL ,μmol/L and HBV-DNA were (93.52±56.31),(4.15±1.54)and lg IU /ml in the observation group, which were lower than those in the control group; the PAT was (63.54±3.69)in the observation group, which was higher than that in the control group, and the differences were statistically significant between groups by comparison (P<0.05). Conclusion Lamivudine in treatment of hepatitis B liver failure has a definite curative effect and can effectively reduce the serum HBV-DNA level and inhibit viral replication.